Quick Comparison
| CJC-1295 (no DAC) | Livagen | |
|---|---|---|
| Half-Life | 0.5 hours | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure |
| Typical Dosage | Standard: 100-300 mcg subcutaneous once to three times daily, typically before bed and/or upon waking. Often combined with Ipamorelin 200-300 mcg in the same injection. Cycled 5 days on, 2 days off, or continuously for 8-12 weeks. | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson cycling rather than continuous use. |
| Administration | Subcutaneous injection | Oral capsule or subcutaneous injection (cycled) |
| Research Papers | 0 papers | 5 papers |
| Categories |
Mechanism of Action
CJC-1295 (no DAC)
CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (at positions 2, 8, 15, and 27) have been made to increase resistance to enzymatic degradation while preserving full biological activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary.
When CJC-1295 binds the GHRH receptor, it activates the Gs alpha subunit, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors that drive GH gene expression and secretion. Importantly, this mechanism preserves the natural pulsatile pattern of GH release because it works within the existing hypothalamic-pituitary feedback loop — somatostatin still provides inhibitory regulation between pulses.
The key advantage of the no-DAC version over the DAC version is this preservation of pulsatility. Because its half-life is approximately 30 minutes, it produces a discrete GH pulse that rises and falls naturally, mimicking the body's own secretory pattern. This pulsatile pattern is believed to be physiologically superior to sustained elevation because GH receptor sensitivity is maintained between pulses, and the liver's IGF-1 production response is optimized by intermittent rather than continuous GH stimulation. This is why CJC-1295 (no DAC) is often preferred by practitioners despite requiring more frequent dosing.
Livagen
Livagen is a short tripeptide (Lys-Glu-Asp) within the Khavinson bioregulator family — peptides hypothesised to regulate gene expression in tissue-specific ways by binding to gene promoter regions. Livagen is positioned as the liver-targeted member of this family, intended to modulate hepatocyte gene expression in ways that support liver regeneration and counteract age-related decline in hepatic function.
Proposed mechanisms include modulation of chromatin condensation states in hepatocyte and lymphocyte nuclei, upregulation of genes involved in hepatic detoxification pathways (cytochrome P450 enzymes, glutathione synthesis), and immunomodulatory effects in liver-resident immune cells. Russian research has reported livagen-induced increases in hepatocyte regeneration markers in animal models of liver injury and changes in lymphocyte chromatin organisation consistent with cellular rejuvenation.
As with all Khavinson tripeptides, the proposed action model is that livagen acts as a transient signalling molecule triggering longer-lasting changes in gene expression. Plasma exposure is brief (around 30 minutes) but downstream transcriptional effects are claimed to persist for weeks, justifying pulse-dosing protocols of 10-30 day courses repeated periodically. The evidence base for clinical efficacy is dominated by Russian gerontology research with limited independent Western replication, and clinical use outside Russia remains largely anecdotal. Livagen should not be used as a substitute for evidence-based liver disease management.
Risks & Safety
CJC-1295 (no DAC)
Common
facial flushing, headache, dizziness, injection site irritation.
Serious
overworking the pituitary gland with excessive doses, theoretical risk of promoting existing tumours through elevated growth hormone.
Rare
allergic reactions, fainting.
Livagen
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; long-term safety in the context of pre-existing liver disease is not established.
Rare
allergic reactions. Like other Khavinson bioregulators, the evidence base is significantly thinner than the marketing suggests.
Full Profiles
CJC-1295 (no DAC) →
One of the most popular growth hormone peptides, often called Mod GRF 1-29. Instead of injecting growth hormone directly, this tells your pituitary gland to release more of its own GH naturally. This is considered healthier than injecting GH directly because your body keeps its normal feedback systems intact. Usually combined with Ipamorelin for much stronger effects — the two work together better than either alone.
Livagen →
A Khavinson tripeptide (Lys-Glu-Asp) developed in Russia as a tissue-specific bioregulator targeting the liver. Promoted for supporting liver regeneration, age-related liver decline, and as part of broader anti-ageing protocols. Sits in the same family as epithalon (pineal), cortagen (brain), and pinealon (pineal/brain). Most evidence is from Russian preclinical work — rigorous Western clinical trials are essentially nonexistent.